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Spinal muscular atrophy (SMA), an autosomal recessive neuromus-
cular disease, is the leading monogenic cause of infant mortality.
Homozygous loss of the gene survival of motor neuron 1 (SMN1)
causes the selective degeneration of lower motor neurons and sub-
sequent atrophy of proximal skeletal muscles. The SMN1 protein
product, survival of motor neuron (SMN), is ubiquitously expressed
and is a key factor in the assembly of the core splicing machinery.
The molecular mechanisms by which disruption of the broad func-
tions of SMN leads to neurodegeneration remain unclear. We used
an antisense oligonucleotide (ASO)-based inducible mouse model of
SMA to investigate the SMN-specific transcriptome changes associ-
ated with neurodegeneration. We found evidence of widespread
intron retention, particularly of minor U12 introns, in the spinal cord
of mice 30 d after SMA induction, which was then rescued by a
therapeutic ASO. Intron retention was concomitant with a strong
induction of the p53 pathway and DNA damage response, manifest-
ing as γ-H2A.X positivity in neurons of the spinal cord and brain.
Widespread intron retention and markers of the DNA damage re-
sponse were also observed with SMN depletion in human SH-SY5Y
neuroblastoma cells and human induced pluripotent stem cell-derived
motor neurons. We also found that retained introns, high in GC con-
tent, served as substrates for the formation of transcriptional R-loops.
We propose that defects in intron removal in SMA promote DNA
damage in part through the formation of RNA:DNA hybrid structures,
leading to motor neuron death.
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Spinal muscular atrophy (SMA) is a devastating autosomalrecessive neuromuscular disease characterized by the pro-
gressive loss of α-motor neurons from the medial ventral horn of the
spinal cord (1). The most common form of SMA, type I, manifests
by age 6 mo as an advancing proximal paralysis that leads to re-
spiratory distress, and affected children generally require permanent
ventilation or succumb to the disease by age 2 y (2). Consequently,
SMA is the most frequent monogenic cause of infant mortality, with
a prevalence of approximately 1 in 10,000 live births (1). In recent
years, much progress has been made in understanding the genetic
and molecular underpinnings of the disease.
SMA is caused by homozygous mutation or deletion of the
survival of motor neuron 1 (SMN1) gene (3). In humans, the
paralogous SMN2 gene arose from a gene duplication event and
is located centromeric to the SMN1 locus. The two paralogs are
nearly identical but differ by several key nucleotides within and
flanking exon 7 (4). As a result, transcripts arising from the SMN2
locus predominantly splice out exon 7, producing a protein that is
rapidly degraded and thought to be nonfunctional; however, a small
fraction of transcripts include exon 7 and encode a protein identical
to SMN1 (5). Importantly, SMN2 copy number varies across indi-
viduals and is a modifier of disease severity, with a higher copy
number leading to reduced severity. We previously characterized
the function of an antisense oligonucleotide (ASO) that binds and
blocks an exonic splicing silencer in exon 7 of SMN2 pre-mRNA,
enhancing the inclusion of exon 7 and the production of full-length
protein when delivered to the cerebrospinal fluid in an inducible
mouse model of type I SMA (6, 7). We found that early treatment
with an ASO that promoted SMN2 exon 7 inclusion prevented and
reversed the gene expression changes that occurred on disease in-
duction (6). Recently, nusinersen, an ASO drug that promotes exon
7 inclusion, was approved to treat all forms of SMA.
With the rapid approval of nusinersen for a broad patient pop-
ulation, a molecular understanding of why SMN loss results in motor
neuron death is critical for monitoring therapeutic efficacy and en-
abling further progress. SMNRNA and protein are widely expressed
during development and in adulthood (4, 8, 9); however, particularly
high expression in ventral motor neurons of the spinal cord from the
second trimester of life into adulthood may imply an increased de-
mand for SMN protein in this cell population (10). SMN has been
shown to play both “housekeeping” and cell type-specific roles in
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ribonucleoprotein (RNP) assembly and RNA metabolism. The most
well-understood role of SMN in the cell is in the assembly of the
spliceosomal small nuclear ribonucleoproteins (snRNPs), which are
required for the catalysis of intron removal during pre-mRNA
splicing (11, 12). In vivo, SMN forms a complex composed of
Gemins 2–8 and Unr-interacting protein (Unrip) that can be
found localized to nuclear bodies called “gems” at steady state (13,
14). In its active role in the cytoplasm, the SMN complex assem-
bles a heptameric ring of Sm proteins around each U-rich small
nuclear RNA (snRNA) (U1, U2, U4, U4atac, U5, U11, or U12) to
form a mature snRNP (15). These assembled snRNPs can then
catalyze splicing on translocation to the nucleus. Several groups
have suggested a function for SMN beyond a role in splicing, in
the assembly of axonal granules and mRNA transport within
axons (16–18). Although this may partially explain the neuronal
bias of SMA pathology, conclusive evidence of how SMN-
dependent axonal transport contributes specifically to the SMA
motor neuron phenotype remains to be determined.
Previous studies have focused on the link between snRNP as-
sembly and splicing defects, and howmissplicing of specific transcripts
from SMN loss can lead to motor neuron dysfunction in SMA.
Consistent with a fundamental role for SMN in snRNP assembly,
Dreyfuss et al. (19) identified distinct patterns of aberrant splicing by
exon array analysis across several tissues of a severe mouse model of
SMA and attributed these defects to tissue-specific alterations in
snRNA levels. Presymptomatic SMA mice exhibit motor neuron-
specific skipping of the agrin Z exons, which are involved in post-
synaptic organization of acetylcholine receptors at the neuromuscular
junction and may contribute to the NMJ defects seen in human pa-
tients (20). Other models have suggested that locomotor defects
arising from SMN loss are independent of defective snRNP bio-
genesis, and that developmental delays in SMN-deficient animals are
responsible for such apparent splicing differences (21, 22).
Inconsistencies in transcriptome changes between models, as
well as evidence that many of these splicing changes are sec-
ondary to SMN loss (23), warrant a closer examination of the
nature of the transcriptomic defects occurring in SMA and their
relation to the SMA phenotype. Several previous studies, in-
cluding ours, have reported strong up-regulation of Cdkn1a/p21,
a cyclin-dependent kinase inhibitor and mediator of cell cycle
arrest downstream of p53, as well as other regulators of cell cycle
and DNA repair in SMA models (6, 19, 23–25). Whereas the
Cdkn1a up-regulation has been attributed to a p53-independent
stabilization of Cdkn1a transcript in the absence of SMN protein
(26, 27), few other gene expression changes can be explained by
such posttranscriptional regulation.
In an effort to understand the link between RNA processing
changes and gene-level changes in SMA and to further investigate
the Cdkn1a activation, we characterized spinal cord transcriptome
changes by RNAseq at high depth in an ASO-mediated inducible
mouse model of type I SMA, which bypasses confounding de-
velopmental changes (6, 7). Expanding on the aforementioned
studies showing snRNP assembly defects and splicing changes, we
found that thousands of introns in functionally diverse genes were
retained in a manner correlating with splice site strength, such that
introns with weaker splicing signals were more sensitive to SMN
depletion. Importantly, we found that the p21 activation was part of
a larger p53 response to DNA double-strand breaks that occurred in
the absence of overt apoptosis in both the mouse model and in two
human cell culture systems.
Here we propose a unifying model whereby defects in RNA pro-
cessing, particularly in intron retention, trigger DNA damage and
subsequent neurodegeneration through the formation of transcrip-
tional R-loops. We found increased R-loops over introns retained on
SMN knockdown in SH-SY5Y cells, as well as downstream of tran-
scription termination sites, extending a recent study suggesting a di-
rect role for SMN in R-loop resolution (28). Our results argue for a
broad role for SMN in the prevention of genome instability and
neurodegeneration through the proper control of RNA processing.
Results
SMN Depletion Induces a Specific Subset of Splicing Changes. The
demonstrated role of SMN in the assembly of spliceosomal snRNPs
suggests that splicing dysregulation may be an early hallmark of
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SMA. We previously described a mouse model of SMA in which
severe SMA is induced in adult Smn−/− mice expressing four copies
of human SMN2 by intracerebroventricular administration of an
ASO mediating the skipping of exon 7 from the human SMN2
transgene (6, 7). In the model, 8-wk-old mice were treated with a
control oligonucleotide or the disease-inducing ASO (“control” or
“skip” ASO) for 20 or 30 d. A second cohort of 8-wk-old mice were
injected with the control or skip ASO, then injected with a thera-
peutic ASO to reverse exon 7 skipping at day 20, 25, or 30 and killed
at day 54 (Fig. 1 A and B). RNA was extracted from whole spinal
cord from each cohort and analyzed by exon array as in our previous
study (6).
To obtain higher-resolution splicing and gene expression data
in this model, we generated poly(A)-mRNA libraries from the
same spinal cord samples and sequenced 50-bp paired-end reads
to a depth of ∼40 M fragments per sample. The direction of
changes in gene expression was concordant between the RNAseq
and exon arrays, although RNAseq provided a wider dynamic
range of expression changes (Fig. S1A). We analyzed tran-
scriptome-wide splicing changes between control and skip ASO
at days 20 and 30 postinjection using the rMATS algorithm (29)
and Gencode version M4 transcript annotations. Of the splicing
categories measured, the largest number of changes occurred in
skipped exons (229 significant changes at day 30), followed by
retained introns (224 changes); however, the proportion of de-
tectable alternative events that was significantly altered in each
class was much greater for retained introns than for skipped
exons (9.45% vs. 0.83%) (Fig. 1C).
Pervasive Retention of Major- and Minor-Class Introns.Owing to the
large proportion of introns showing significant retention at day
30, we next focused on characterizing this subset of splicing
events. We first quantified intron retention transcriptome-wide,
not limited to annotated retained introns, for major- and minor-
class introns. Novel annotations for rMATS were constructed
from Gencode vM4 transcript annotations, allowing the possible
retention of all unique annotated introns. Annotations of mouse
U12 introns were generated similarly from the U12DB (30).
Using these annotations, we found that nearly 4% of all introns
were significantly retained at 30 d after injection of the skip ASO
(Fig. 2A). Global intron retention was also confirmed using a second
splicing algorithm, MISO (31), with 1,935 introns (1.2% of detected
introns) showing significantly increased retention on SMN depletion
at day 30 and 211 introns showing increased splicing. Along with
driving the assembly of the major spliceosomal snRNPs, SMN also
has been implicated in assembling the snRNPs that compose the
minor spliceosome, including U11 and U12 (19). Nearly one-third of
all U12 introns in the spinal cord of day 30 SMA mice showed
significantly increased levels of retention, consistent with a role for
SMN in regulating the minor spliceosome (Fig. 2A). Importantly,
intron retention was reversed or prevented by delivery of the ther-
apeutic ASO, with earlier administration resulting in a greater de-
gree of proper splicing (Fig. 2B).
We also performed a parallel induction experiment to understand
the time course of splicing and gene expression changes using 15-wk-
old mice that were injected with the control or skip oligo and aged
for 10, 20, or 30 d. Spinal cords were then harvested and processed
for RNA analysis as described previously (6). As expected, the levels
of intron retention increased between 10 d and 30 d postinduction
(Fig. S2 A and B). Taken together with the findings from the rescue
experiment, these data demonstrate that intron removal is directly
correlated with SMN expression.
To understand whether intron retention is a primary effect of
SMN loss, we analyzed various characteristics of introns impacted
by SMN depletion. We hypothesized that direct mRNA targets
arising from splicing dysregulation would be less likely to belong to
specific biological functions and would be structurally similar,
whereas indirect targets might fall within particular pathways and
impact gene expression as a result of activation of a developmental
process or stress response (32–35). Analysis of splice site strength
showed that introns with greater degrees of retention had weaker
5′ and 3′ splice sites, as determined by consensus to canonical
5′ and 3′ splice site sequences (36), and retained introns were
significantly higher in GC content compared with expression- and
length-matched control introns (Fig. 2 C and D).
Although genes containing significantly retained introns were
on average more highly expressed than control genes (Fig. S3A),
they were not enriched for any gene ontology terms and showed
similar fold changes in gene expression between control and skip
ASO conditions at day 30 as seen in genes containing control
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introns (Fig. S3B). This finding suggests that intron retention on
SMN depletion does not directly function as a coordinated gene
expression response. Furthermore, whereas intron retention is
frequently a characteristic of last introns owing to the kinetics of
splicing and polyadenylation (35), the distribution of SMN-
dependent retained introns was not biased toward any particular
location within transcripts (Fig. S3C). Taken together, these
results suggest that intron retention arising from SMN depletion
is likely to be a direct consequence of disrupted spliceosome
function rather than a result of secondary activation of a gene
regulatory pathway in response to SMN loss.
p53 Activation Occurs Early After SMN Depletion.Gene ontology analysis
using Ingenuity Pathway Analysis (Qiagen; qiagenbioinformatics.com)
of genes with significant expression changes at 20 d postinjection
revealed significant activation of the p53 pathway (Fig. 3A). The p53
signature was driven in part by a 5.71-fold increase in expression
of Cdkn1a, or p21, a cyclin-dependent kinase inhibitor that
mediates cell cycle inhibition. This is in agreement with the
Cdkn1a up-regulation previously found in microarray analysis
of spinal cord RNA from this model (6) (Fig. S1B). This sig-
nature persisted to day 30 postinduction (Fig. 3B) and was
accompanied by up-regulation of early apoptotic markers, in-
cluding Fas and Pidd1 (Fig. S4A), suggesting that p53 induction
was preceding, and likely triggering, the activation of apoptosis.
In addition to the p53 response, components of the complement
cascade, such as C1Qa/b/c, C3AR1, and C5AR1, were up-regulated
at days 20 and 30, as reflected in the significant enrichment of the
Skip ASO d30 Ctrl ASO d30 
H
ip
po
ca
m
pu
s 
Sp
in
al
 c
or
d 
0.0
0.1
0.2
0.3
0.4
0.5
5
10
15
20
25
%
 P
os
itiv
e 
Ne
ur
on
al
 N
uc
le
i
Skip ASO d30 Control ASO d30
30um 30um
30um 30um
p = 0.0237
Threshold
0.0 1.0 2.0 3.0 4.0 5.0 6.0
-log(B-H p-value)
Threshold
A B
C
D
p53 Signaling
TREM1 Signaling
Chemokine Signaling
Role of Pattern Recognition Receptors 
in Recognition of Bacteria and Viruses
-log(B-H p-value)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
Role of Pattern Recognition Receptors 
in Recognition of Bacteria and Viruses
TREM1 Signaling
Complement System
p53 Signaling
Acute Phase Response Signaling
LXR/RXR Activation
Toll-like Receptor Signaling
IL-6 Signaling
p38 MAPK Signaling
Death Receptor Signaling
Interferon Signaling
Eicosanoid Signaling
HMGB1 Signaling
IL-8 Signaling
Apoptosis Signaling
VDR/RXR Activation
Estrogen-mediated S-phase Entry
Leukocyte Extravasation Signaling
PPAR Signaling
Glioma Invasiveness Signaling
Induction of Apoptosis by HIV1
Antioxidant Action of Vitamin C
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages
Cytotoxic T Lymphocyte-mediated 
Apoptosis of Target Cells
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation
LPS/IL-1 Mediated Inhibition of 
RXR Function
Fc  Receptor-mediated Phagocytosis 
in Macrophages and Monocytes
Fig. 3. p53 pathway activation and immune clearance signals over time. (A and B) Enriched gene ontology terms at day 20 (A) and day 30 (B). Benjamini–
Hochberg corrected P value < 0.05; activation/repression absolute z-score >0.5. (C) Brain and spinal cord of mice treated with skip or control (Ctrl) ASO were
harvested at day 30 and fixed and sectioned for immunohistochemistry analysis. Sections were stained with an antibody against γ-H2A.X, a marker for DNA
double-strand breaks. Punctate staining in skip day 30 samples represents positive γ-H2A.X loci. (D) Quantification of % pyramidal neurons in the hippo-
campus staining positive for γ-H2A.X.
E2350 | www.pnas.org/cgi/doi/10.1073/pnas.1613181114 Jangi et al.
“pattern recognition receptors” ontology class. Although activa-
tion of complement was previously reported in motor neurons
of presymptomatic severe SMA mice and was attributed to
aberrant synaptic pruning (20), our results do not preclude a
contribution of complement secreted from glial cells within the
spinal cord, along with the possibility of endogenous neuronal
complement causing overpruning.
DNA Double-Strand Breaks in Spinal Cord and Brain of SMA Mice.We
next sought to address the nature of p53 activation by assessing the
various pathways feeding into and resulting from the p53 response.
Intracellular and extracellular stresses, such as hypoxia, oncogenic
stress, and DNA damage, can lead to phosphorylation of p53 and
up-regulation of its downstream transcriptional targets. Depending
on the nature of the insult and degree of cellular damage, this can
result in cell cycle arrest or apoptosis. We first looked for markers of
DNA damage, cell cycle arrest, and apoptosis in the CNS of SMA
mice at 30 d after injection of ASO using immunohistochemistry.
Surprisingly, we found evidence for DNA double-strand breaks as
measured by γ-H2A.X foci throughout the hippocampus and in
interneurons in the spinal cord (Fig. 3C). Within the hippocampus,
12.11% of pyramidal neurons showed positive γ-H2A.X staining in
SMN ASO-treated mice at day 30 postinjection, whereas only
0.13% of pyramidal neurons stained positive in control ASO-
treated mice (Fig. 3D). Cyclin D1, the activation of which is re-
quired for progression through the G1/S phase transition of the cell
cycle and has been postulated to be reactivated in postmitotic
neurons in response to DNA damage (37), showed a similar
staining pattern in the brain and spinal cord (Fig. S4B).
Despite this DNA damage and the up-regulation of apoptotic
markers at the RNA level, we did not detect any evidence of
apoptosis in either of these tissues, with virtually no cells in brain
or spinal cord staining positive for the apoptotic marker cleaved
caspase-3. This suggests that at day 30, neurons in the brain and
spinal cord had accumulated DNA damage but were not ac-
tively undergoing apoptosis.
Human Cell Culture Models of Acute SMN Depletion Recapitulate
Splicing Defects and DNA Damage. To determine whether the in-
tron retention and DNA double-strand breaks seen in our SMA
mouse model can be translated to humans, we established two
human cell culture models to assess the effects of acute SMN
loss. We stably infected SH-SY5Y human neuroblastoma cells
and human induced pluripotent stem cell (hiPSC)-derived motor
neurons (hiPSC-MNs) with lentiviral vectors expressing short-
hairpin RNA (shRNA) targeting SMN1/2 under the control of a
doxycycline-inducible promoter. After 7 and 5 d of shRNA
induction, respectively, both SH-SY5Y cells and hiPSC-MNs
showed appreciable depletion of SMN protein compared with a
nontargeting control shRNA (Fig. 4A and Fig. S5A). SH-SY5Y
cells also showed an accumulation in the G0/G1 phase of the cell
cycle that correlated with activation of p21 (Fig. S4C).
We next performed mRNAseq on these samples in duplicate
and analyzed gene expression and splicing changes between
control and SMN knockdown conditions in both cell lines.
Pathway analysis by Ingenuity Pathway Analysis on significantly
changing genes revealed that for SH-SY5Y and hiPSC-MNs,
transient knockdown of SMN resulted in activation of a DNA
double-strand break response, indicated by activation of targets
of BRCA1, a key player in double-strand break repair (Fig. 4B
and Fig. S5B). Interestingly, we failed to observe the up-regu-
lation of complement components that had been detected in the
SMA mouse model. This suggests that complement activation is
a non–cell-autonomous effect of the interaction between neu-
ronal cells and glia and might not be intrinsic to motor neurons,
and that it may be an indirect effect of SMN depletion.
We next quantified splicing changes, specifically global intron
retention, in SH-SY5Y cells and hiPSC-MNs depleted of SMN.
Splicing and gene expression changes were of smaller magnitude
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in the iPSC-MNs than in the SH-SY5Y cells, perhaps because
of the shorter time point of SMN depletion and the lack of
cell division in the iPSC-MNs. Despite this, consistent with our
observations in the SMA mouse model, all introns, as well as the
U12 subset of introns, demonstrated significantly increased av-
erage retention on SMN knockdown in both cell lines (Fig. 4C
and Fig. S5C). Furthermore, in support of a direct effect of SMN
loss on minor intron retention arising from defects in snRNP
assembly, knockdown of SMN in SH-SY5Y cells resulted in a
significant decrease in minor spliceosomal snRNA U11 (Fig. S6).
Of note, only eight of the significantly retained introns in mouse
spinal cord and human SH-SY5Y cells were shared between both
datasets, implying that the conserved DNA damage effect is not
dependent on the identity of the retained introns, but rather that
the global stress of widespread intron retention may be the driving
force in this signature. Considered together, these results suggest
that preventing DNA damage by promoting proper splicing is
likely to be a conserved function of SMN that is disrupted in SMA.
R-Loop Induction on SMN Depletion. Several recent studies have
proposed that defects in mRNA processing can contribute to
genome instability (14, 28, 38). One proposed mechanism for this
effect is through the failure to resolve transcriptional R-loops,
transient RNA:DNA hybrid structures that form during tran-
scription that displace the nontemplate DNA strand and gen-
erate susceptibility to DNA damage if stabilized. R-loop
formation is limited by the rapid association of RNA-binding
proteins with the nascent RNA during transcription and splicing,
preventing hybridization to the DNA template, and is actively
resolved by RNA:DNA helicase activity and RNase H1/H2 ac-
tivity (39, 40). The presence of G-rich nontemplate strands can
stabilize R-loops by folding into G-quadruplexes and further
contribute to double-strand break formation (39, 41). Knock-
down of RNA splicing and transport factors has been associated
with increased R-loop formation and DNA damage (42, 43). Sim-
ilarly, we found that splicing inhibition by the small molecule pla-
dienolide B caused accumulation of γ-H2A.X in a time-dependent
manner (Fig. S7A). Based on this finding, we hypothesized that
intron retention arising from SMN depletion may lead to DNA
damage through the formation of R-loop intermediates at retained
intron loci, which we had found to have increased GC content.
To test this model, we assayed R-loop formation genome-wide
in SH-SY5Y cells expressing the control or SMN shRNA using
DNA-RNA immunoprecipitation (IP) sequencing (DRIPseq),
which enriches for hybrid structures in the chromatin using the
R-loop–specific antibody S9.6 (44). We also performed DRIPseq
on samples immunoprecipitated with mouse IgG as a control for
specific enrichment. Normalizing to this negative control, we
identified 6,315 regions as significantly enriched across two
replicates in nontargeting control (shCtrl) cells, representing the
basal level of R-loop formation in SH-SY5Y cells. In shSMN1
cells, 10,163 regions were significantly enriched in both repli-
cates, showing that loss of SMN resulted in a 1.6-fold increase in
global R-loop formation (Fig. 5A). Comparing the distribution
of R-loops across genomic regions, we found that R-loops
were significantly enriched in gene-associated regions in SMN
knockdown cells compared with control knockdown cells (P <
2.2e-16, χ2 test) (Fig. S7B).
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We next normalized DRIPseq peak distributions to a set of
randomly distributed peak regions. Although the DRIPseq peaks
were depleted across all introns, in retained introns they were
4.8-fold enriched over the random distribution in shCtrl cells and
5.6-fold enriched in shSMN1 cells, indicating that R-loops are
specifically enriched over retained introns (Fig. 5B). Because this
difference in enriched peaks occurring in retained introns between
control and SMN knockdown cells is not statistically significant,
this perhaps reflects a high basal level of R-loop formation in
these regions. However, examination of individual examples of
major and minor introns with significant retention revealed ac-
cumulation of DRIPseq reads in SMN knockdown cells compared
with control cells (Fig. 5 C and D). Furthermore, when we spe-
cifically measured normalized DRIPseq read coverage across re-
gions of interest, we detected significantly higher DRIPseq read
coverage across introns that were retained on SMN depletion
compared with a control set of length- and expression-matched
introns, suggesting that intron retention does indeed correlate
with increased propensity to form R-loops, and that SMN de-
pletion leads to increased R-loop formation (Fig. 5E).
It has been observed that R-loops are involved in transcript
termination (45), and a recent study proposed that SMN re-
cruitment of the RNA:DNA helicase senataxin may enhance
R-loop resolution at transcription termination sites (28). Consistent
with these findings, a significantly larger fraction of peaks in SMN
knockdown cells were located within a region 1 kb downstream
of genes compared with peaks in control cells (19.8% vs. 17.9%;
P = 0.002) (Fig. S7B). Specific enrichment flanking transcription
termination sites on SMN depletion was also verified through
metagene analysis (Fig. S7C). Motif analysis of enriched DRIPseq
regions in shSMN cells revealed T-rich motifs, which are found
near transcript termination sites (46). We also detected a G-rich
motif consistent with G-quadruplex–forming regions, suggesting
that these regions are in fact more likely to form stable R-loops
through the formation of G-quadruplexes (Fig. S7D).
We next asked whether the DNA damage signature detectable in
SH-SY5Y cells arises from R-loops. To test this, we sought to rescue
DNA double-strand breaks, measured by H2A.X phosphorylation,
by repairing R-loops with RNase H1 overexpression. RNase H1 has
been demonstrated to be sufficient to repair R-loops in cell culture
(42). We overexpressed tagged human RNase H1 in control or
SMN knockdown cells or in cells treated with the splicing inhibitor
pladienolide B and assayed γ-H2A.X levels. Indeed, we found that
RNase H1 overexpression partially suppressed the increased
γ-H2A.X signal seen in SMN knockdown cells, suggesting at least
part of the DNA damage signal arises from the R-loops (Fig. 5F).
Acute treatment with pladienolide B also resulted in activation of
γ-H2A.X, and this was prevented or suppressed by RNase H1
overexpression. These results support our hypothesis that de-
creases in splicing efficiency, such as those caused by SMN de-
ficiency or direct splicing inhibition, may cause genome instability
and activation of a DNA damage response through R-loop
formation.
Discussion
Here we have characterized a prevalent intron retention and DNA
damage signature in an inducible mouse model of SMA, as well as
in human SMA cell culture systems. As an alternative to the para-
digm in the field attributing motor neuron deficits in type I SMA to
alternative splicing changes in specific target transcripts, we present
a unifying model in which inefficiencies in RNA processing, man-
ifested primarily as intron retention, lead to DNA damage through
the formation of RNA:DNA hybrids (Fig. 6). Although we cannot
formally rule out the possibility that the splicing changes that we
observed are indirect effects of SMN loss (23), our computational
and experimental analyses suggest that SMN depletion causes sys-
tematic defects in intron removal. We found that both U2 and U12
introns were retained in mouse and cell culture models of SMA,
with a bias toward retention of U12 introns, and that minor snRNAs
showed decreased expression on SMN depletion. This bias may be
explained by the observation that snRNAs of the minor spliceosome
are two orders of magnitude less abundant than snRNAs of the
major spliceosome (47) and may be disproportionately affected by
SMN depletion because of the stoichiometry of major and minor
spliceosome components. Introns preferentially retained on SMN
depletion in SH-SY5Y cells were enriched in R-loops compared with
spliced introns. RNA and protein signatures of DNA double-strand
breaks were also detectable in SMAmice and in the human cell lines,
and overexpression of RNase H1, which resolves R-loops, partially
rescued DNA breaks in SH-SY5Y cells depleted of SMN. Based on
this evidence, we propose that DNA damage in type I SMA is trig-
gered by R-loop formation resulting from defects in intron removal.
The extent of intron retention and DNA damage is likely correlated
with SMN expression levels, and as a result these observations may be
relevant in intermediate models of type II or type III SMA.
Several previous studies have focused on individual splicing
events as drivers of SMA pathogenesis in motor neurons (19, 20,
48). Although it is likely that the cohort of tissue-specific alter-
native splicing changes in SMA contributes to the sensitivity of
motor neurons to cell death (19), we propose that the phenome-
non of global intron retention is a distinct cause of cellular stress
proximal to SMN loss. We observed that intron retention was
rescued by the therapeutic ASO, indicating that these splicing
changes are directly dependent on SMN expression levels. Unlike
retained introns that trigger NMD on export of the transcript to
the cytoplasm (34), SMN-dependent retained introns in our
mouse model did not have a significant effect on expression of the
genes containing them. This finding suggests that they are ulti-
mately spliced out in the nucleus, perhaps more slowly than other
introns owing to their weaker splicing signals, yet their reduced
splicing kinetics in the absence of SMNmay be sufficient to trigger
cellular stress. There was also minimal overlap between the set of
retained introns in the mouse model and the human cell culture
models despite striking concordance in DNA damage response
gene expression signatures. These observations argue for a more
critical role in the process of stochastic intron retention than in the
specific identity of retained introns. Interestingly, Ackerman et al.
(49) recently demonstrated that mutation of one of the multicopy
U2 snRNA genes resulted in retention of short introns across
broad gene ontologies and subsequent neurodegeneration, further
implicating intron retention in neuronal stress.
Numerous hypotheses have been put forth to explain the ac-
tivation of the DNA damage response in neurodegeneration. In
some cases, mutations in DNA damage response and repair
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Fig. 6. Intron retention as a mechanism for DNA damage induction. Model
for splicing dysregulation as a modulator of R-loop formation and DNA
damage. Depletion of proteins in green induces DNA double-strand breaks,
and depletion of proteins in blue induces R-loop formation.
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components themselves are the causative factors in DNA damage
accumulation (50). For example, the neurologic disorder ataxia-
telangiectasia is caused by mutations in ATM, the serine-threonine
kinase responsible for coordinating the double-strand break re-
sponse (51). Similarly, mutations in the single-strand break re-
pair gene aprataxin (APTX) cause one of the most common
forms of spinocerebellar ataxia, ataxia with oculomotor apraxia 1
(52, 53). Notably, despite being germline mutations in ubiquitous
DNA damage response genes, both diseases display primarily
neurologic deficits, suggesting a particular sensitivity of the ner-
vous system to defects in the DNA damage response.
Other sources of DNA damage, particularly in age-related neu-
rodegeneration, can be attributed to oxidative stress. The high rate
of oxygen consumption by the brain results in increased production
of reactive oxygen species with age, and oxidative DNA damage is
emerging as a hallmark of both Alzheimer’s disease and Parkinson’s
disease (54, 55). Induction of oxidative stress results in activation of
p38 MAPK and initiates an oxidative stress transcriptional response.
We failed to detect activation of p38 in our human cell culture
models of SMA and detected only a subtle transcriptional signature
of p38 activation in the mouse spinal cord at day 30, suggesting that
oxidative stress is not a prominent player in these systems and is
unlikely to be the cause of DNA damage.
More recently, evidence has been accumulating for the in-
volvement of cotranscriptional R-loops and DNA damage
in several neurodegenerative diseases, perhaps most strikingly in
motor neuron diseases. R-loops form normally in many circum-
stances, including Ig class switch recombination and transcription
termination, and are actively resolved by RNA:DNA helicases and
RNase H1 and H2 (39, 56). Persistent R-loops can become del-
eterious, however. These aberrant R-loops are generally stabilized
by the formation of G-quadruplexes in the displaced, G-rich
nontemplate strand, which can trigger gene down-regulation or
DNA double-strand breaks through as-yet unclear mechanisms
(39, 41). To date, two distinct mechanisms for R-loop formation in
neurodegeneration have been proposed, depending on the genetic
insult. In the case of repeat expansion diseases, such as the c9orf72
G4C2 hexanucleotide repeat that is the most common genetic le-
sion in both sporadic and familial amyotrophic lateral sclerosis
(ALS), the repeat itself forms R-loops when transcribed, causing
abortive transcription at the c9orf72 locus (57). The GAA repeats
in frataxin that cause Friedreich ataxia have also been shown to
form R-loops in vitro, and it is likely that other G-rich repeat
expansions also cause gene silencing and potentially form focal
DNA breaks in an R-loop–dependent manner (58).
The other proposed mechanism is widespread aberrant R-loop
formation owing to mutations in components of the R-loop for-
mation or resolution pathways. It was recently shown that SMN
recruits senataxin, an RNA:DNA helicase involved in R-loop res-
olution, to transcription termination sites (28). Intriguingly, sen-
ataxin itself is mutated in a juvenile-onset form of ALS, designated
ALS4, that bears a striking resemblance to SMA and results in loss
of motor neurons in early childhood (59). An additional RNA:DNA
helicase, IGHMBP2, was initially characterized in the context of
R-loop–dependent class-switch recombination, but it has since been
found that loss-of-function mutations in IGHMBP2 cause spinal
muscular atrophy type I with respiratory distress (60, 61). These two
independent lines of genetic evidence, in addition to our results,
provide strong support for the causative role of unresolved R-loops
in motor neuron disease.
The conspicuous enrichment of mutations in RNA-binding
proteins in neuromuscular disease begs the question of whether
there is a common defect in RNA metabolism across this spec-
trum of illnesses. Mutations in the RNA-binding protein genes
TDP43, FUS, and ATXN2 have been associated with sporadic and
familial forms of ALS. These proteins shuttle between the nucleus
and cytoplasm and have multiple roles in RNA metabolism, in-
cluding transcription, splicing, and mRNA transport. In addition,
all of these factors, as well as SMN, have been found in cyto-
plasmic stress granules, dynamic sites of translational repression
that form rapidly during cellular stress (62, 63). A hallmark of
ALS pathology is the appearance of cytoplasmic ubiquitinated
aggregates of TDP-43 in the brain and spinal cord. These aggre-
gates occasionally contain FUS protein as well, and FUS muta-
tions can independently lead to FUS aggregate formation. The
identity of these aggregates, and whether they are distinct from
stress granules, remain to be determined (64). In addition, mutant
FUS sequesters SMN in the cytoplasm and causes altered snRNA
levels and splicing changes, some of which are consistent with
SMN loss on its own (65). SMN itself has been shown to induce
stress granule assembly on overexpression (66), and Ataxin2 also
interacts with several RNA-binding proteins, including FUS and
TDP-43, and localizes to stress granules (67).
One potential model for a shared mechanism across these ge-
netic defects is that the induction of aggregates or stress granules
sequesters these shuttling proteins away from their nuclear func-
tions. Consequently, defects in splicing, RNA processing, and
transport would be expected. Perhaps consistent with this idea,
FUS and TDP-43 were recently implicated in the prevention of
R-loop–mediated transcription-associated DNA damage in models
of ALS (68). As we have demonstrated here, changes in RNA
processing due to either to cytoplasmic aggregation or genetic
deletion of splicing factors could initiate the formation of DNA
double-strand breaks in part through R-loops, leading ultimately
to the degeneration of motor neurons in both ALS and SMA.
Several open questions stemming from our observations and
findings of others remain to be addressed. One outstanding issue is
the specificity of the pathology to motor neurons in the face of
mutations in ubiquitously expressed genes. Although the sensitivity
of this cell type to genomic instability owing to inefficient repair
machinery is a tantalizing explanation, it is possible that additional
functions of SMN contribute to the motor neuron specificity. This
possibility has been suggested by SMA models of SMN point
mutations that recapitulate motor neuron degeneration in the
absence of defects in snRNP assembly (69). Alternatively, there
likely is less prominent pathology in other cell types (70).
Second, the relative contributions of intron retention, tran-
scription termination defects, and other RNA processing defects
to R-loop formation in SMA remain unclear. SMN may directly
mediate R-loop resolution through the recruitment of senataxin,
as demonstrated previously (28). Alternatively, we present a
model wherein G-rich retained introns arising indirectly from
SMN loss are putative substrates for R-loop formation. Further
study is needed to elucidate whether intron retention synergizes
with other defects in RNA processing to initiate DNA damage
when SMN is deficient. Most importantly, it will be necessary to
further dissect whether manipulation of R-loop formation and
subsequent DNA damage can be a viable therapeutic option in
SMA. Targeting this pathway in combination with SMN resto-
ration may provide additional benefit to patients beyond the
benefit from SMN restoration alone. If indeed SMA pathogen-
esis and ALS pathogenesis share this mode of DNA damage
induction and neurodegeneration, then such therapeutic mo-
dalities would have broad implications for motor neuron disease.
Materials and Methods
Western Blot Analysis. Protein from SH-SY5Y cellswas extractedwith RIPA buffer
containing protease and phosphatase inhibitors, resolved on 4–12% Bis-Tris gels
(Novex), and probed with the following antibodies: mouse anti-vinculin (clone
VIN-11–5; Sigma-Aldrich, V4505), mouse anti-SMN (BD Biosciences, 610647),
rabbit anti–γ-H2A.X (Abcam, ab11174), mouse anti-RNase H1 (Abcam, ab56560),
rabbit anti-p21 (Cell Signaling Technology, 2947), and rabbit anti-p53 (Cell Sig-
naling Technology, 9282).
Immunohistochemistry. Spinal cord and brain from control and SMA mice
were fixed with 4% (vol/vol) formaldehyde in PBS overnight. Fixed tissue was
soaked in 30% (wt/vol) sucrose overnight at 4 °C and embedded in frozen
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medium. The Ventana XT slide staining system was used to stain 10-μm
sections. For detection of γ-H2A.X, rabbit anti–γ-H2A.X (S139) (R&D Systems,
AF2288) was used at 0.25 μg/mL. Secondary staining was done using
OmniMap anti-Rb HRP (Roche, 760–4311).
Lentiviral Transduction. SMARTchoice lentiviral particles of doxycycline-
inducible shRNAs targeting SMN1 [catalog no. VSH6376: V2IHSPGG_743120
(shSMN1), V2IHSPGG_743128 (shSMN2)] or a nontargeting control [VSC6580
(shCtrl)] under the PGKpromoter and constitutively expressingGFPwere purchased
from Dharmacon. SH-SY5Y cells were incubated in concentrated viral supernatant
with 4 μg/mL polybrene (EMDMillipore, TR-1003-G) for 5 h, then viral supernatant
was diluted fourfold in fresh Complete Medium. At 24 h postinfection, medium
was changed to fresh medium containing 1 μg/mL puromycin. Selection was
continued for 5 d. Cells were expanded and frozen as pools of infected cells. For
hiPSC-MNs, cells were differentiated in a 12-well format, then infected overnight
without polybrene. The medium was changed daily for 3 d without puromycin
selection. For both SH-SY5Y and hiPSC-MNs, fluorescence microscopy indicated
nearly 100% infection efficiency as assessed by GFP expression.
mRNA Sequencing Sample Isolation and Preparation. Total RNA from spinal cord,
lentivirally infected SH-SY5Y cells induced for 7 d with doxycycline, or lentivirally
infectedhiPSC-MNcells induced for 5 dwithdoxycyclinewas extractedusingTRIzol
(Thermo Fisher Scientific, 15596026) and the Direct-zol RNA MiniPrep Kit (Zymo
Research, R2050). Then 50–500 ng of DNase-treated total RNA, with a Universal
Human Reference RNA as control, were used to construct libraries using the
TruSeq Stranded mRNA HT Sample Prep Kit (Illumina, RS-122-2103) with barcodes
for sample multiplexing. The products were purified and enriched with PCR for 13
cycles to create final cDNA libraries. Libraries were quantified using the HT DNA
Reagent Kit (Caliper Life Sciences, 760435) on a LabChip GX automated gel
electrophoresis system (PerkinElmer). Multiplexed libraries were equimolarly
pooled, diluted to a 2 nM pool for final analysis on Agilent High-Sensitivity DNA
Kit to run on one rapid flow cell per lane, and sequenced using 2 × 50-nucleotide
paired-end runs of the Illumina HiSeq 2500 platform.
Reverse-Transcription and qPCR Measurement of snRNAs. Total RNA was
extracted from lentivirally infected SH-SY5Y cells induced for 7 d with
doxycycline and DNase treated using the Directzol RNA MiniPrep Plus Kit
(Zymo Research). snRNAs were quantified as in Zhang et al. (19). In brief,
cDNAs were synthesized from each sample using gene-specific reverse pri-
mers and 100 ng of total RNA (375 ng of total RNA for minor snRNAs). Real-
time qPCR was performed for each snRNA and normalized to 5S rRNA using
SYBR Green chemistry on an Applied Biosystem QuantStudio 12K Flex Real-
Time PCR system. Triplicate total RNA samples were harvested from each
knockdown sample and propagated through cDNA preparation and qPCR
assays. Details of primer sets are presented in Table S1.
Transfections. SH-SY5Y cells expressing lentiviral shRNA against control or
SMN cells were induced for 4 d with 1 μg/mL doxycycline. Cells were trans-
fected with pCMV6-Entry (OriGene, PS100001) or FLAG-Myc–tagged human
RNase H1 (OriGene, RC200595) using Lipofectamine 3000 (Thermo Fisher
Scientific, L3000008). Protein was harvested after 48 h using RIPA buffer and
analyzed by Western blot analysis.
DRIPseq. DRIPseq was performed as described (71) with the following changes.
In brief, nucleic acids isolated from ∼2 × 106 cells were digested with a re-
striction enzyme mixture (50 units each of BsrGI, XbaI, EcoRI, HindIII, and SspI)
overnight at 37 °C in 1× CutSmart Buffer (New England BioLabs). Digests were
purified by phenol/chloroform extraction, and 8.8 μg of digested DNA per cell
culture condition was treated with 3 μL of RNase H overnight at 37 °C. For each
condition, 4.4 μg of RNase H-treated or untreated DNA was immunoprecipi-
tated with 10 μg of S9.6 antibody (Kerafast, ENH001), washed three times with
IP buffer, eluted, treated with Proteinase K and phenol/chloroform-extracted.
Resulting samples were sonicated using a Bioruptor Pico sonicator (Dia-
genode), with 11 cycles of 15 s on/90 s off. Fragments were prepared for se-
quencing using the NEBNext Ultra II Library Prep Kit for Illumina (New England
BioLabs) with barcodes for sample multiplexing. Pooled libraries were se-
quenced on the Illumina NextSeq platform.
Derivation of hiPSCs and Differentiation into Motor Neuron Cultures. Human
iPSCs were derived from lymphoblastoid cell lines (Coriell Biorepository) with the
Epi5 Episomal iPSC Reprogramming Kit (Life Technologies) and propagated in
mTeSR Medium (Stem Cell Technologies) on Matrigel (Life Technologies). The
pluripotency of the hiPSCs was confirmed by staining for pluripotency markers
and in vitro differentiation into three germ layers. Differentiation of hiPSCs into
motor neuron cultures was carried out as described previously (72), with slight
modifications. In brief, hiPSC colonies were dissociated with EDTA and placed in
suspension in low-adhesion flasks (Corning) to form embryoid bodies in medium
consisting of DMEM/F12/ Neurobasal medium (Life Technologies), N2 supple-
ment (Life Technologies), B27 supplement (Life Technologies), ascorbic acid
(20 μM), and β-mercaptoethanol (0.055 mM). The medium was changed every
other day, and small molecules were added for neuronal patterning [0.2 μM
LDN193189, 40 μM SB431542, and 3 μM CHIR99021); motor neuron induction
(1 μM retinoic acid, 0.5 μM agonist of hedgehog signaling (SAG), and 10 μM of
the drug DAPT]. On day 14, EBs were dissociated into single cells with papain
and plated on Matrigel or poly D-lysin/laminin-coated plates in medium con-
taining neurotrophic factors [20 ng/mL brain-derived neurotrophic factor
(BDNF), 10 ng/mL glial cell-derived neurotrophic factor (GDNF), and 10 ng/mL ciliary
neurotrophic factor (CNTF)].
RNAseq Gene Expression and Splicing Analysis. RNAseq reads were mapped
with the STAR algorithm, aligning to the Gencode version M4 transcript an-
notation for mouse spinal cord RNA and the hg38 annotation for SH-SY5Y cells
and hiPSC-MNs. We used parameters–alignIntronMin 20–alignIntronMax
1000000–outFilterMismatchNmax 999–outFilterMismatchNoverLmax 0.05–
outFilterMultimapNmax 20–alignSJoverhangMin 8–alignSJDBoverhangMin
1–alignMatesGapMax 1000000–sjdbOverhang 49. Aligned reads were assigned
to transcripts from the aforementioned annotations using RSEM, and resulting
raw read counts were input into DESeq2 for differential gene expression analysis
using default parameters.
For general splicing analysis, BAM files produced from STARmappingwere
input into rMATS, using the Gencode version M4 transcript annotation for
mouse spinal cord RNA and the hg38 annotation for SH-SY5Y and hiPSC-MN
RNA samples. For detection of intron retention, human and mouse anno-
tations were generated containing all consecutive spliced and unspliced
exon-intron-exon triads from hg38 and Gencode vM4. To measure the re-
tention of U12 introns, we generated a second set of annotations by fil-
tering this novel set of annotations for introns that overlapped exactly with
human and mouse U12 introns extracted from U12DB. These annotations
were used to call intron retention in mouse spinal cord, SH-SY5Y, and hiPSC-
MN RNAseq datasets using rMATS. A false discovery rate (FDR) cutoff of 0.05
was used to define significantly differentially spliced regions.
Bioinformatic Analyses. Custom Python and R scripts were used to determine
intronic GC enrichment, expression of genes containing retained introns,
genic distribution of retained introns, and DRIPseq metagene plots. BedTools
(73) was used to determine the genomic distribution of DRIPseq regions.
Cell Cycle Analysis. SH-SY5Y cells stably transduced with a nontargeting
shRNA or shRNAs targeting SMN1/2 were induced to express shRNA for 7 d
with 1 μg/mL doxycycline. Cells were then treated for 4 h with DMSO or
50 μM etoposide. A total of 1 × 105 cells per sample were trypsinized, fixed in
cold 70% EtOH, and incubated in 0.1% Triton X-100 with 200 μg/mL RNase A
and 20 μg/mL propidium iodide. Cells were analyzed by flow cytometry to
determine the proportions of cell populations in distinct stages of the cell
cycle based on DNA content.
ACKNOWLEDGMENTS. We thank Christopher Henderson for providing
helpful guidance and discussion, and staff at Biogen Translational Pathology
for conducting the immunohistochemistry studies. This work was supported
in part by the St. Giles Foundation and the SMA Foundation (A.R.K.). Biogen
and Ionis Pharmaceuticals provided funding for the acquisition, analysis, and
interpretation of data. Biogen reviewed and provided feedback on the
manuscript to the authors, and all authors provided their approval of
the manuscript.
1. Talbot K, Davies KE (2001) Spinal muscular atrophy. Semin Neurol 21(2):189–197.
2. Birnkrant DJ, Pope JF, Martin JE, Repucci AH, Eiben RM (1998) Treatment of type I
spinal muscular atrophy with noninvasive ventilation and gastrostomy feeding.
Pediatr Neurol 18(5):407–410.
3. Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K (1997) Genomic variation and
gene conversion in spinal muscular atrophy: Implications for disease process and
clinical phenotype. Am J Hum Genet 61(1):40–50.
4. Lefebvre S, et al. (1995) Identification and characterization of a spinal muscular atrophy-
determining gene. Cell 80(1):155–165.
5. Burnett BG, et al. (2009) Regulation of SMN protein stability. Mol Cell Biol 29(5):
1107–1115.
6. Staropoli JF, et al. (2015) Rescue of gene-expression changes in an induced mouse
model of spinal muscular atrophy by an antisense oligonucleotide that promotes
inclusion of SMN2 exon 7. Genomics 105(4):220–228.
Jangi et al. PNAS | Published online March 7, 2017 | E2355
CE
LL
BI
O
LO
G
Y
PN
A
S
PL
U
S
7. Sahashi K, et al. (2013) Pathological impact of SMN2 mis-splicing in adult SMA mice.
EMBO Mol Med 5(10):1586–1601.
8. Coovert DD, et al. (1997) The survival motor neuron protein in spinal muscular atrophy.
Hum Mol Genet 6(8):1205–1214.
9. Lefebvre S, et al. (1997) Correlation between severity and SMN protein level in spinal
muscular atrophy. Nat Genet 16(3):265–269.
10. Tizzano EF, Cabot C, Baiget M (1998) Cell-specific survival motor neuron gene expression
during human development of the central nervous system: Implications for the patho-
genesis of spinal muscular atrophy. Am J Pathol 153(2):355–361.
11. Wahl MC, Will CL, Lührmann R (2009) The spliceosome: Design principles of a dynamic
RNP machine. Cell 136(4):701–718.
12. Burghes AH, Beattie CE (2009) Spinal muscular atrophy: Why do low levels of survival
motor neuron protein make motor neurons sick? Nat Rev Neurosci 10(8):597–609.
13. Pellizzoni L (2007) Chaperoning ribonucleoprotein biogenesis in health and disease.
EMBO Rep 8(4):340–345.
14. Li DK, Tisdale S, Lotti F, Pellizzoni L (2014) SMN control of RNP assembly: From post-
transcriptional gene regulation to motor neuron disease. Semin Cell Dev Biol 32:22–29.
15. Pellizzoni L, Yong J, Dreyfuss G (2002) Essential role for the SMN complex in the
specificity of snRNP assembly. Science 298(5599):1775–1779.
16. Fallini C, et al. (2011) The survival of motor neuron (SMN) protein interacts with the
mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary
motor neuron axons. J Neurosci 31(10):3914–3925.
17. Zhang HL, et al. (2003) Active transport of the survival motor neuron protein and the
role of exon-7 in cytoplasmic localization. J Neurosci 23(16):6627–6637.
18. Fallini C, Bassell GJ, Rossoll W (2012) Spinal muscular atrophy: The role of SMN in
axonal mRNA regulation. Brain Res 1462:81–92.
19. Zhang Z, et al. (2008) SMN deficiency causes tissue-specific perturbations in the repertoire
of snRNAs and widespread defects in splicing. Cell 133(4):585–600.
20. Zhang Z, et al. (2013) Dysregulation of synaptogenesis genes antecedes motor neuron
pathology in spinal muscular atrophy. Proc Natl Acad Sci USA 110(48):19348–19353.
21. Garcia EL, Lu Z, Meers MP, Praveen K, Matera AG (2013) Developmental arrest of
Drosophila survival motor neuron (Smn) mutants accounts for differences in expres-
sion of minor intron-containing genes. RNA 19(11):1510–1516.
22. Praveen K, Wen Y, Matera AG (2012) A Drosophila model of spinal muscular atrophy
uncouples snRNP biogenesis functions of survival motor neuron from locomotion and
viability defects. Cell Reports 1(6):624–631.
23. Bäumer D, et al. (2009) Alternative splicing events are a late feature of pathology in a
mouse model of spinal muscular atrophy. PLoS Genet 5(12):e1000773.
24. Corti S, et al. (2008) Neural stem cell transplantation can ameliorate the phenotype of
a mouse model of spinal muscular atrophy. J Clin Invest 118(10):3316–3330.
25. Ruggiu M, et al. (2012) A role for SMN exon 7 splicing in the selective vulnerability of
motor neurons in spinal muscular atrophy. Mol Cell Biol 32(1):126–138.
26. Hubers L, et al. (2011) HuD interacts with survival motor neuron protein and can
rescue spinal muscular atrophy-like neuronal defects. Hum Mol Genet 20(3):553–579.
27. Tadesse H, Deschênes-Furry J, Boisvenue S, Côté J (2008) KH-type splicing regulatory
protein interacts with survival motor neuron protein and is misregulated in spinal
muscular atrophy. Hum Mol Genet 17(4):506–524.
28. Zhao DY, et al. (2016) SMN and symmetric arginine dimethylation of RNA polymerase
II C-terminal domain control termination. Nature 529(7584):48–53.
29. Shen S, et al. (2014) rMATS: robust and flexible detection of differential alternative
splicing from replicate RNA-Seq data. Proc Natl Acad Sci USA 111(51):E5593–E5601.
30. Alioto TS (2007) U12DB: A database of orthologous U12-type spliceosomal introns.
Nucleic Acids Res 35(Database issue):D110–D115.
31. Katz Y, Wang ET, Airoldi EM, Burge CB (2010) Analysis and design of RNA sequencing
experiments for identifying isoform regulation. Nat Methods 7(12):1009–1015.
32. Braunschweig U, et al. (2014) Widespread intron retention in mammals functionally
tunes transcriptomes. Genome Res 24(11):1774–1786.
33. Shalgi R, Hurt JA, Lindquist S, Burge CB (2014) Widespread inhibition of post-
transcriptional splicing shapes the cellular transcriptome following heat shock. Cell
Reports 7(5):1362–1370.
34. Wong JJ, et al. (2013) Orchestrated intron retention regulates normal granulocyte
differentiation. Cell 154(3):583–595.
35. Yap K, Lim ZQ, Khandelia P, Friedman B, Makeyev EV (2012) Coordinated regulation
of neuronal mRNA steady-state levels through developmentally controlled intron
retention. Genes Dev 26(11):1209–1223.
36. Yeo G, Burge CB (2004) Maximum entropy modeling of short sequence motifs with
applications to RNA splicing signals. J Comput Biol 11(2-3):377–394.
37. Park DS, et al. (1998) Cyclin-dependent kinases participate in death of neurons
evoked by DNA-damaging agents. J Cell Biol 143(2):457–467.
38. Paulsen RD, et al. (2009) A genome-wide siRNA screen reveals diverse cellular pro-
cesses and pathways that mediate genome stability. Mol Cell 35(2):228–239.
39. Aguilera A, García-Muse T (2012) R loops: From transcription byproducts to threats to
genome stability. Mol Cell 46(2):115–124.
40. Li X, Manley JL (2006) Cotranscriptional processes and their influence on genome
stability. Genes Dev 20(14):1838–1847.
41. Duquette ML, Handa P, Vincent JA, Taylor AF, Maizels N (2004) Intracellular tran-
scription of G-rich DNAs induces formation of G-loops, novel structures containing G4
DNA. Genes Dev 18(13):1618–1629.
42. Denis MM, et al. (2005) Escaping the nuclear confines: Signal-dependent pre-mRNA
splicing in anucleate platelets. Cell 122(3):379–391.
43. Domínguez-Sánchez MS, Barroso S, Gómez-González B, Luna R, Aguilera A (2011)
Genome instability and transcription elongation impairment in human cells depleted
of THO/TREX. PLoS Genet 7(12):e1002386.
44. Ginno PA, Lott PL, Christensen HC, Korf I, Chédin F (2012) R-loop formation is a distinctive
characteristic of unmethylated human CpG island promoters. Mol Cell 45(6):814–825.
45. Skourti-Stathaki K, Proudfoot NJ, Gromak N (2011) Human senataxin resolves RNA/
DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent ter-
mination. Mol Cell 42(6):794–805.
46. Chou ZF, Chen F, Wilusz J (1994) Sequence and position requirements for uridylate-rich
downstream elements of polyadenylation signals. Nucleic Acids Res 22(13):2525–2531.
47. Montzka KA, Steitz JA (1988) Additional low-abundance human small nuclear ribo-
nucleoproteins: U11, U12, etc. Proc Natl Acad Sci USA 85(23):8885–8889.
48. Lotti F, et al. (2012) An SMN-dependent U12 splicing event essential for motor circuit
function. Cell 151(2):440–454.
49. Jia Y, Mu JC, Ackerman SL (2012) Mutation of a U2 snRNA gene causes global dis-
ruption of alternative splicing and neurodegeneration. Cell 148(1-2):296–308.
50. Madabhushi R, Pan L, Tsai LH (2014) DNA damage and its links to neurodegeneration.
Neuron 83(2):266–282.
51. Shiloh Y, Ziv Y (2013) The ATM protein kinase: Regulating the cellular response to
genotoxic stress, and more. Nat Rev Mol Cell Biol 14(4):197–210.
52. Date H, et al. (2001) Early-onset ataxia with ocular motor apraxia and hypoalbuminemia
is caused by mutations in a new HIT superfamily gene. Nat Genet 29(2):184–188.
53. Moreira MC, et al. (2001) The gene mutated in ataxia-ocular apraxia 1 encodes the
new HIT/Zn-finger protein aprataxin. Nat Genet 29(2):189–193.
54. Sanders LH, et al. (2014) Mitochondrial DNA damage: Molecular marker of vulnerable
nigral neurons in Parkinson’s disease. Neurobiol Dis 70:214–223.
55. Lovell MA, Markesbery WR (2007) Oxidative DNA damage in mild cognitive impair-
ment and late-stage Alzheimer’s disease. Nucleic Acids Res 35(22):7497–7504.
56. Wahba L, Amon JD, Koshland D, Vuica-Ross M (2011) RNase H and multiple RNA
biogenesis factors cooperate to prevent RNA:DNA hybrids from generating genome
instability. Mol Cell 44(6):978–988.
57. Haeusler AR, et al. (2014) C9orf72 nucleotide repeat structures initiate molecular
cascades of disease. Nature 507(7491):195–200.
58. Grabczyk E, Mancuso M, Sammarco MC (2007) A persistent RNA.DNA hybrid formed
by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP
in vitro. Nucleic Acids Res 35(16):5351–5359.
59. Chen YZ, et al. (2004) DNA/RNA helicase gene mutations in a form of juvenile
amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 74(6):1128–1135.
60. Grohmann K, et al. (2001) Mutations in the gene encoding immunoglobulin mu-
binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. Nat
Genet 29(1):75–77.
61. Fukita Y, et al. (1993) The human S mu bp-2, a DNA-binding protein specific to the
single-stranded guanine-rich sequence related to the immunoglobulin mu chain
switch region. J Biol Chem 268(23):17463–17470.
62. Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and
FTD: Disrupted RNA and protein homeostasis. Neuron 79(3):416–438.
63. Lagier-Tourenne C, Cleveland DW (2009) Rethinking ALS: The FUS about TDP-43. Cell
136(6):1001–1004.
64. Han H, et al. (2013) MBNL proteins repress ES-cell-specific alternative splicing and
reprogramming. Nature 498(7453):241–245.
65. Sun S, et al. (2015) ALS-causative mutations in FUS/TLS confer gain and loss of func-
tion by altered association with SMN and U1-snRNP. Nat Commun 6:6171.
66. Hua Y, Zhou J (2004) Survival motor neuron protein facilitates assembly of stress
granules. FEBS Lett 572(1-3):69–74.
67. Salvi JS, Mekhail K (2015) R-loops highlight the nucleus in ALS. Nucleus 6(1):23–29.
68. Hill SJ, et al. (2016) Two familial ALS proteins function in prevention/repair of tran-
scription-associated DNA damage. Proc Natl Acad Sci USA 113(48):E7701–E7709.
69. Garcia EL, Wen Y, Praveen K, Matera AG (2016) Transcriptomic comparison of Dro-
sophila snRNP biogenesis mutants reveals mutant-specific changes in pre-mRNA
processing: Implications for spinal muscular atrophy. RNA 22(8):1215–1227.
70. Fayzullina S, Martin LJ (2014) Skeletal muscle DNA damage precedes spinal motor
neuron DNA damage in a mouse model of spinal muscular atrophy (SMA). PLoS One
9(3):e93329.
71. Loomis EW, Sanz LA, Chedin F, Hagerman PJ (2014) Transcription-associated R-loop
formation across the human FMR1 CGG-repeat region. PLoS Genet 10(4):e1004294.
72. Maury Y, et al. (2014) Combinatorial analysis of developmental cues efficiently con-
verts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol
33(1):89–96.
73. Quinlan AR, Hall IM (2010) BEDTools: A flexible suite of utilities for comparing
genomic features. Bioinformatics 26(6):841–842.
E2356 | www.pnas.org/cgi/doi/10.1073/pnas.1613181114 Jangi et al.
